Clinical Trials Logo

Clinical Trial Summary

This study an open label prospective observational cohort study to evaluate the safety and efficacy of sodium citrate 4% locking solution in preventing central line associated blood stream infection in children requiring long term central venous catheters for home parenteral nutrition. Sodium citrate 4% is FDA-approved for dialysis catheters, but has not been formally evaluated for use in tunneled catheters for parenteral nutrition. The rate of central line-associated bloodstream infection (CLABSI) and other potential adverse events will be monitored for 12 months, with the option to remain in the study for a longer period of time.


Clinical Trial Description

In this prospective observational cohort study of pediatric patients requiring home parenteral nutrition for intestinal failure, participants will be enrolled from the pediatric intestinal rehabilitation clinic, and data collection will be obtained from the electronic medical record. Participant will receive daily sodium citrate 4% catheter locking solution for CLABSI prophylaxis, instead of heparin locks. Participants will be monitored for 12 months for adverse events, including CLABSI. Participants will have the same routine laboratory schedule and monthly outpatient follow up. After 12 months, participants will be given the option to continue to use sodium citrate 4% locks after the initial study period if no serious adverse events have occurred. The investigators anticipate enrolling 10-15 participants per year and anticipate enrollment to continue for 3-5 years. Sodium citrate locks: 3 ml vials of locking solution will be prepared by the infusion pharmacy using commercially available 4% sodium citrate IV fluid (available in 500 ml bags). The sodium citrate locks will be instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition. If subjects are hospitalized, sodium citrate locks will be temporarily held during the duration of the inpatient stay, and will be resumed once the participant is discharged home. ;


Study Design


Related Conditions & MeSH terms

  • CLABSI - Central Line Associated Bloodstream Infection
  • Sepsis

NCT number NCT04756427
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase Phase 4
Start date March 28, 2022
Completion date November 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06085690 - Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science N/A
Completed NCT04534348 - Study on the Reduction of Catheter-related Infections by Use of Self-disinfecting Venous and Arterial Access Caps
Recruiting NCT06365528 - Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes N/A
Completed NCT04927325 - Erythema at Exit Site & Tablet Camera N/A
Active, not recruiting NCT03730883 - The Effect of Early Versus Standard Central Line Removal on Growth of Very Low Birth Weight Premature Infants N/A
Recruiting NCT05959018 - Efficacy & Cost Effectiveness of Antimicrobial-impregnated CVCs in CLABSI Prevention in a Malaysia Adult ICU N/A